medigraphic.com
ISSN 1810-2352 (Print)

2011, Number 1

<< Back Next >>

Rev Cub Med Int Emerg 2011; 10 (1)

Streptokinase without albumin is a new alternative for thromboembolism treatment of myocardial acute infarction

García MA, Trueba RD, Mendoza OJL, Gil AM, Álvarez TO

Language: Spanish
References: 16
Page: 1998-2005
PDF size: 118.67 Kb.


ABSTRACT

Introduction: The streptokinase with albumin has been assessed in different studies in patients with acute myocardial infarction (AMI); the formula used contained human serum albumin as stabilizer. The Center of Genetic and Biotechnology Engineering has developed a new formula without albumin with the advantage to avoid the use of hemoderivatives.
Objectives: To assess the effectiveness of the recombinant streptokinase (rSK) without albumin in treatment of myocardial acute infarction.
Method: A cohort, longitudinal, descriptive and prospective study was conducted in 96 patients diagnosed with myocardial acute infarction admitted in the special care unit of the “Dr. Luis Diaz Soto” Central Military Hospital between January and July, 2009. The cases were divided into two groups and treated in a randomized way with streptokinase with and without insulin. The appearance of adverse reactions in both groups was analyzed, as well as its intensity and severity and mortality at 30 days.
Results: Appearance of adverse reactions was slightly greater in the group of patients treated with rSK with albumin for a 21,2 % in whose group 9 patients quit the treatment: 13.63 % of them in 4 (6.06 %) temporarily and 5 patients (7.57 %) with a definite interruption of thrombolytic treatment. In the group treated with streptokinase without albumin the treatment was interrupted in three occasions (10 %) but only in a temporary way.
Conclusions: Streptokinase without albumin is effective and produce less adverse effects than the rSK with albumin used until now, nevertheless it is necessary to conduct multicenter studies with inclusion of a great number of patients.


REFERENCES

  1. Young JJ. Rev Cardiovasc Med 2003; 4 (4):216-27.

  2. Llerena L, Llerena R, Rodríguez de la Vega A, Valdés-Rucabado JA, Fernández- Felipe R, Rodríguez-Bereau C, et al. Trombólisis intracoronaria con Estreptoquinasa Recombinante (SK-R) en el infarto agudo del miocardio. XVII Congreso Nacional de Cardiología, Guadalajara, Jalisco (México) Septiembre 29-Octubre 3, 1991.

  3. GISSI (Grupo Italiano per lo Studio de lla Streptochinasi nell´Infarto Miocardico) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401.

  4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349- 60.

  5. Lee K, Woodlief L, Topol E, Weaver D, Betriu A. (GUSTO-I investigators). Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41021 patients. Circulation 1995; 91: 1659-1668.

  6. The TERIMA Group Investigators. Multicenter, randomised, comparative study of recombinant vs. natural streptokinases in acute myocardial infarct. Thromb Haemost 1999; 82(6):1605-9.

  7. The TERIMA Group of Investigator. TERIMA-2: national extension of thrombolytic treatment with recombinant streptokinase in acute myocardial infarct in Cuba. Thromb Haemost 2000; 84(6):949-54.

  8. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003. Disponible en: http://www.ctep.cancer.gov.

  9. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312:932-6.

  10. Noble S, McTavish D. Reteplase. Drugs 1996; 52: 589-605.

  11. Goldstein P. Management of prehospital thrombolytic therapy in ST-segment elevation acute coronary syndrome (< 12 hours). Minerva Anestesiol. 2005 Jun; 71(6):297-302.

  12. Reeder GS, Kennedy HS, Rosenson RS. Overview of the management of suspected myocardial infarction. UpToDate v9.1, 2001.

  13. Braunwald: Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed., 1114- 1207. W. B. Saunders Company, 2001

  14. Simmons ML. Cardiovascular disease in Europe: Challenges for the medical profession. Opening address of the 2002 Congress European Society of Cardiology. Eur Heart J. 2003; 24: 8-12.

  15. Herlitz J, Hartford M, Aune S, Karlsson T. Occurrence of hypotension during streptokinase infusion in suspected acute myocardial infarction, and its relation to prognosis and metoprolol therapy. Am J Cardiol 1993; 71:1021-4.

  16. Lew AS, Laramee P, Cercek B, Shah PK, Ganz W. The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation 1985; 72:1321-6.




2020     |     www.medigraphic.com